Inactive Instrument

Press Releases Reviva Pharmaceuticals Holdings, Inc. Nasdaq

Equities

TZAC

US76152G1004

Press Releases

Unlock all the news: Be the first to know and act before the market!

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH	31/05	PR
Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	28/05	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH	23/05	PR
Reviva to Participate in the BIO International Convention	21/05	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH	17/05	PR
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia	15/05	AQ
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights	14/05	AQ
Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference	13/05	AQ
RVPH INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH	11/05	PR
Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting	09/05	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH	07/05	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH	28/04	PR
RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH	25/04	BU
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia	15/04	AQ
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights	15/04	AQ
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting	26/03	AQ
Reviva to Present at the UBS Virtual CNS Day	11/03	AQ
Reviva to Present at the 36th Annual ROTH Conference	07/03	AQ
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference	20/02	AQ
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia	06/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Reviva Pharmaceuticals Holdings, Inc. Nasdaq

Equities

TZAC

US76152G1004

Press Releases

Filters